Parkinson’s Disease (PD) is a neurodegenerative disorder that affects millions of people worldwide. It is characterized by the progressive loss of dopamine-producing cells in the brain, leading to motor symptoms such as tremors, stiffness, and bradykinesia. However, a lesser-known complication of PD is Parkinson’s Disease Psychosis (PDP), which affects approximately 50% of patients over the course of their illness. The market for Parkinson’s Disease Psychosis treatment has witnessed significant growth in recent years, driven by the rising prevalence of PD and the increasing recognition of PDP as a debilitating condition. As the population ages, the number of individuals affected by PD is expected to rise, thereby fueling the demand for effective PDP treatments. The current standard of care for Parkinson’s Disease Psychosis includes the use of antipsychotic medications, which can lead to worsened motor symptoms and increased mortality in Parkinson’s Disease patients. Acadia Pharmaceuticals, a leading biopharmaceutical company, recognized this unmet medical need and developed NUPLAZID (pimavanserin) specifically for the treatment of Parkinson’s Disease Psychosis. NUPLAZID is the first and only FDA-approved medication for Parkinson’s Disease Psychosis, offering a novel approach that does not exacerbate motor symptoms. One concern surrounding NUPLAZID is its high cost. The price of the medication has been a subject of debate and scrutiny within the healthcare industry. The reasons for its high cost can be attributed to the extensive research and development process, including clinical trials and regulatory approvals. Additionally, the relatively small patient population and limited competition in the PDP treatment market also contribute to the pricing of NUPLAZID. Despite the challenges posed by high costs, the introduction of NUPLAZID has significantly improved the treatment landscape for Parkinson’s Disease Psychosis patients. As research continues to unravel the complex mechanisms underlying PDP, new drug targets may emerge, leading to the development of more effective and affordable treatments.Furthermore, ongoing studies are exploring the potential of repurposing existing medications used in other neurodegenerative diseases like Alzheimer’s Disease and Lewy Body Dementia for the treatment of Parkinson’s Disease Psychosis. Leveraging knowledge and experience gained from these related conditions could provide valuable insights into managing PDP.In conclusion, the Parkinson’s Disease Psychosis treatment market is witnessing a positive shift with the introduction of NUPLAZID. While the cost of the medication remains a concern, it represents a significant advancement in addressing the unmet needs of PDP patients. Continued research, innovation, and collaboration within the pharmaceutical industry hold the key to unlocking further breakthroughs in PDP treatment. As we move forward, it is crucial to prioritize patient-centric approaches and work towards improving the quality of life for individuals living with Parkinson’s Disease Psychosis. Monkeypox MarketDelveInsight’s “Monkeypox Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Patient Monitoring Devices MarketPatient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.Typhoid MarketDelveInsight’s “Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Zika Virus MarketDelveInsight’s “Zika Virus Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Latest Reports By DelveInsightHypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma MarketTo know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting Recent Blog’s By DelveInsight: Insights Into The Cutaneous T-cell Lymphoma Treatment MarketRoche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment LandscapeEmerging Role of Digital Health in the Field of OncologyHow Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment LandscapeHow are Technological Trends and Innovations Reshaping the Dementia CareAssessing the Major Growth and Ongoing Developments in the Clinical Diagnostics MarketNon-opioid Analgesics Chronic Pain Treatment: Savior of Underserved PatientsLimited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment MarketEvaluating the Key Trends and Technologies Shaping the Future of DentistryEpidemiology Insights and Projection of Parkinson’s Disease Psychosis
Market Insights and Projections of Parkinson’s Disease Psychosis
Parkinson’s Psychosis Treatment: Addressing Unmet Needs
Why is NUPLAZID So Expensive?
The Future of Parkinson’s Disease Psychosis Treatment
Latest Reports By DelveInsight-
Category: Uncategorized
-
-
In an era of digital transformation, the healthcare industry is no exception when it comes to adopting technological advancements. One such advancement is the transition from traditional paper-based health records to electronic health records (EHRs). The digitization of patient data brings numerous advantages, but it also presents unique challenges. In this blog post, we will explore the world of EHRs, their benefits, major players in the market, and the challenges they face.
What is an Electronic Health Record (EHR)?
An Electronic Health Record (EHR) is a digital version of a patient’s paper-based medical records. It includes comprehensive information such as medical history, diagnoses, treatments, medications, allergies, and laboratory results. EHRs are designed to be accessed and shared by authorized healthcare providers, enabling seamless collaboration and continuity of care.
What is the major advantage of using Electronic Health Records (EHR)?
The adoption of EHRs brings numerous advantages to healthcare providers and patients alike. One major advantage is the improved accessibility and availability of patient information. With EHRs, healthcare professionals can quickly access patient records from anywhere, leading to faster and more accurate diagnoses and treatment decisions. EHRs also facilitate better coordination among healthcare providers, reducing medical errors and improving patient outcomes.
Major Players in the Electronic Health Records (EHRs) Market
The electronic health records market is rapidly expanding, and several major players dominate this space. Companies like Epic Systems, Cerner Corporation, Allscripts, and Athenahealth are leading the charge in developing robust EHR systems. These companies invest heavily in research and development to enhance their products and provide innovative solutions that cater to the evolving needs of healthcare providers.
Electronic Health Records (EHRs) Market Assessment and Future Outlook
The global electronic health records market is projected to witness significant growth in the coming years. Factors such as the increasing adoption of EHRs, government initiatives to promote healthcare IT, and the growing demand for data-driven healthcare services are driving market expansion. Furthermore, the integration of advanced technologies like artificial intelligence (AI), machine learning (ML), and blockchain into EHR systems holds great promise for improving efficiency, data security, and clinical decision-making.
Electronic Health Records Benefit and Challenges
While the benefits of EHRs are evident, there are also challenges that need to be addressed. One major challenge is the interoperability of EHR systems. As healthcare providers and systems use different EHR platforms, the seamless exchange and integration of patient data become complex. Standardization efforts and the development of interoperability frameworks are underway to tackle this challenge.
Another challenge is the proper handling and protection of sensitive patient data. As EHRs contain a vast amount of personal health information, ensuring data privacy and security is of utmost importance. The integration of blockchain technology into EHRs shows promise in providing enhanced data security and traceability.
In conclusion, the transition from paper-based health records to electronic health records brings numerous advantages to the healthcare industry. Improved accessibility, coordination, and data-driven insights are transforming the way healthcare is delivered. However, challenges like interoperability and data security must be addressed to fully harness the potential of EHRs. As technology continues to advance, the future of EHRs looks promising, with artificial intelligence, machine learning, and blockchain playing pivotal roles in shaping the future of healthcare.
Latest Reports By DelveInsight-
Monkeypox Market
DelveInsight’s “Monkeypox Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Patient Monitoring Devices Market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.
Typhoid Market
DelveInsight’s “Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market
DelveInsight’s “Zika Virus Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Latest Reports By DelveInsight
Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market
To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting
Recent Blog’s By DelveInsight:
- Insights Into The Cutaneous T-cell Lymphoma Treatment Market
- Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
- Emerging Role of Digital Health in the Field of Oncology
- How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
- How are Technological Trends and Innovations Reshaping the Dementia Care
- Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
- Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
- Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
- Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
-
Chondrosarcoma is a rare form of cancer that originates in the bones and cartilage. It accounts for approximately 20% of all bone tumors and is commonly found in adults between the ages of 30 and 60. Chondrosarcoma poses significant challenges in terms of treatment and diagnosis, and patients often face a long and difficult journey in finding effective therapies. However, a promising candidate called INBX-109, developed by Inhibrx, is expected to enter the US market in 2026, offering hope to chondrosarcoma patients.
The challenges in chondrosarcoma treatment and diagnosis
Diagnosing chondrosarcoma can be challenging due to its resemblance to other bone tumors. This often leads to delayed diagnosis and treatment initiation. Additionally, the rarity of the disease makes it difficult to conduct clinical trials and develop effective treatment strategies. Limited awareness among healthcare professionals and patients further adds to the burden of chondrosarcoma.
A glimpse of chondrosarcoma subtypes and grades
Chondrosarcoma is classified into various subtypes, including conventional, clear cell, and dedifferentiated. Each subtype has its own characteristics and requires tailored treatment approaches. Moreover, chondrosarcomas are graded based on their aggressiveness, with higher grades indicating a more severe prognosis. Understanding the specific subtype and grade is crucial in determining the appropriate Chondrosarcoma treatment plan.
How do tumor grade and stage shape the chondrosarcoma treatment journey?
Tumor grade and stage play a vital role in guiding the chondrosarcoma treatment journey. Low-grade tumors may be managed through surgery alone, while high-grade tumors often necessitate a combination of surgery, radiation therapy, and chemotherapy. Advanced-stage chondrosarcoma may require systemic therapy and targeted treatments. Individualized treatment plans are formulated based on these factors, taking into account the patient’s overall health and preferences.
What does NCCN recommend for chondrosarcoma treatment?
The National Comprehensive Cancer Network (NCCN) provides treatment guidelines for various cancers, including chondrosarcoma. According to the NCCN guidelines, surgical resection remains the cornerstone of treatment for localized disease. Adjuvant chondrosarcoma therapies, such as radiation therapy or chemotherapy, may be considered based on the tumor grade and stage. For metastatic or unresectable chondrosarcoma, systemic therapies are recommended.
Inhibrx’s INBX-109: Promising candidate for chondrosarcoma treatment
Inhibrx’s INBX-109 is an investigational therapy that holds promise for chondrosarcoma treatment. It is a monoclonal antibody designed to target a specific protein involved in tumor growth and survival. Preclinical studies have shown encouraging results, demonstrating its potential efficacy against chondrosarcoma. The anticipated entry of INBX-109 into the US market in 2026 brings hope for improved treatment outcomes and better quality of life for chondrosarcoma patients.
Unmet need in the chondrosarcoma treatment market
Despite recent advancements, the market for chondrosarcoma treatment still faces significant unmet needs. There is a lack of targeted therapies specifically approved for chondrosarcoma, highlighting the need for innovative treatment options. Moreover, clinical trials for chondrosarcoma are relatively scarce, limiting access to new therapies. Addressing these unmet needs is crucial to improve patient outcomes and reduce the burden of chondrosarcoma.
In conclusion, chondrosarcoma poses numerous challenges in terms of treatment and diagnosis. The rarity of the disease and the complexity of its subtypes and grades make it a formidable
Latest Reports By DelveInsight
Vein Illumination Devices Market
DelveInsight’s ‘Vein Illumination Devices – Market Insight, Competitive Landscape and Market Forecast, 2028’ report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Adrenocortical Carcinoma
DelveInsight’s “Adrenocortical Carcinoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Adrenocortical Carcinoma, historical and forecasted epidemiology as well as the Adrenocortical Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Monkeypox Market
DelveInsight’s “Monkeypox Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Pars Planitis Market
DelveInsight’s “Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Patient Monitoring Devices Market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.
Typhoid Market
DelveInsight’s “Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market
DelveInsight’s “Zika Virus Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Related Reports by DelveInsight-
scedosporium infection market | autoimmune pulmonary alveolar proteinosis market | rosai-dorfman disease market | sandhoff disease market | b-cell chronic lymphocytic leukemia market | bladder cancer market | trichomoniasis market | bile duct cancer market | resorbable vascular scaffold market | salivary gland infection market | ischemic stroke market | paget’s disease market | ventricular assist devices market | vascular stents market | vascular graft devices market | bladder scanners market | b-cell non-hodgkin lymphoma market | basal cell carcinoma market | birch allergy market | vein illumination devices market
To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting
Recent Blog’s By DelveInsight:
- Insights Into The Cutaneous T-cell Lymphoma Treatment Market
- Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
- Emerging Role of Digital Health in the Field of Oncology
- How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
- How are Technological Trends and Innovations Reshaping the Dementia Care
- Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
- Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
- Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
- Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
-
The studio was filled with the rich odour of roses, and when the light summer wind stirred amidst the trees of the garden, there came through the open door the heavy scent of the lilac, or the more delicate perfume of the pink-flowering thorn.
From the corner of the divan of Persian saddle-bags on which he was lying, smoking, as was his custom, innumerable cigarettes, Lord Henry Wotton could just catch the gleam of the honey-sweet and honey-coloured blossoms of a laburnum, whose tremulous branches seemed hardly able to bear the burden of a beauty so flamelike as theirs; and now and then the fantastic shadows of birds in flight flitted across the long tussore-silk curtains that were stretched in front of the huge window, producing a kind of momentary Japanese effect, and making him think of those pallid, jade-faced painters of Tokyo who, through the medium of an art that is necessarily immobile, seek to convey the sense of swiftness and motion. The sullen murmur of the bees shouldering their way through the long unmown grass, or circling with monotonous insistence round the dusty gilt horns of the straggling woodbine, seemed to make the stillness more oppressive. The dim roar of London was like the bourdon note of a distant organ.
In the centre of the room, clamped to an upright easel, stood the full-length portrait of a young man of extraordinary personal beauty, and in front of it, some little distance away, was sitting the artist himself, Basil Hallward, whose sudden disappearance some years ago caused, at the time, such public excitement and gave rise to so many strange conjectures.
As the painter looked at the gracious and comely form he had so skilfully mirrored in his art, a smile of pleasure passed across his face, and seemed about to linger there. But he suddenly started up, and closing his eyes, placed his fingers upon the lids, as though he sought to imprison within his brain some curious dream from which he feared he might awake.
“It is your best work, Basil, the best thing you have ever done,” said Lord Henry languidly. “You must certainly send it next year to the Grosvenor. The Academy is too large and too vulgar. Whenever I have gone there, there have been either so many people that I have not been able to see the pictures, which was dreadful, or so many pictures that I have not been able to see the people, which was worse. The Grosvenor is really the only place.”
“I don’t think I shall send it anywhere,” he answered, tossing his head back in that odd way that used to make his friends laugh at him at Oxford. “No, I won’t send it anywhere.”
Lord Henry elevated his eyebrows and looked at him in amazement through the thin blue wreaths of smoke that curled up in such fanciful whorls from his heavy, opium-tainted cigarette. “Not send it anywhere? My dear fellow, why? Have you any reason? What odd chaps you painters are! You do anything in the world to gain a reputation. As soon as you have one, you seem to want to throw it away. It is silly of you, for there is only one thing in the world worse than being talked about, and that is not being talked about. A portrait like this would set you far above all the young men in England, and make the old men quite jealous, if old men are ever capable of any emotion.”
“I know you will laugh at me,” he replied, “but I really can’t exhibit it. I have put too much of myself into it.”
Lord Henry stretched himself out on the divan and laughed.
“Yes, I knew you would; but it is quite true, all the same.”
“Too much of yourself in it! Upon my word, Basil, I didn’t know you were so vain; and I really can’t see any resemblance between you, with your rugged strong face and your coal-black hair, and this young Adonis, who looks as if he was made out of ivory and rose-leaves. Why, my dear Basil, he is a Narcissus, and you—well, of course you have an intellectual expression and all that. But beauty, real beauty, ends where an intellectual expression begins. Intellect is in itself a mode of exaggeration, and destroys the harmony of any face. The moment one sits down to think, one becomes all nose, or all forehead, or something horrid. Look at the successful men in any of the learned professions. How perfectly hideous they are! Except, of course, in the Church. But then in the Church they don’t think. A bishop keeps on saying at the age of eighty what he was told to say when he was a boy of eighteen, and as a natural consequence he always looks absolutely delightful. Your mysterious young friend, whose name you have never told me, but whose picture really fascinates me, never thinks. I feel quite sure of that. He is some brainless beautiful creature who should be always here in winter when we have no flowers to look at, and always here in summer when we want something to chill our intelligence. Don’t flatter yourself, Basil: you are not in the least like him.”
“You don’t understand me, Harry,” answered the artist. “Of course I am not like him. I know that perfectly well. Indeed, I should be sorry to look like him. You shrug your shoulders? I am telling you the truth. There is a fatality about all physical and intellectual distinction, the sort of fatality that seems to dog through history the faltering steps of kings. It is better not to be different from one’s fellows. The ugly and the stupid have the best of it in this world. They can sit at their ease and gape at the play. If they know nothing of victory, they are at least spared the knowledge of defeat. They live as we all should live—undisturbed, indifferent, and without disquiet. They neither bring ruin upon others, nor ever receive it from alien hands. Your rank and wealth, Harry; my brains, such as they are—my art, whatever it may be worth; Dorian Gray’s good looks—we shall all suffer for what the gods have given us, suffer terribly.”
“Dorian Gray? Is that his name?” asked Lord Henry, walking across the studio towards Basil Hallward.
“Yes, that is his name. I didn’t intend to tell it to you.”
-
“Oh, I can’t explain. When I like people immensely, I never tell their names to any one. It is like surrendering a part of them. I have grown to love secrecy. It seems to be the one thing that can make modern life mysterious or marvellous to us. The commonest thing is delightful if one only hides it. When I leave town now I never tell my people where I am going. If I did, I would lose all my pleasure. It is a silly habit, I dare say, but somehow it seems to bring a great deal of romance into one’s life. I suppose you think me awfully foolish about it?”
“Not at all,” answered Lord Henry, “not at all, my dear Basil. You seem to forget that I am married, and the one charm of marriage is that it makes a life of deception absolutely necessary for both parties. I never know where my wife is, and my wife never knows what I am doing. When we meet—we do meet occasionally, when we dine out together, or go down to the Duke’s—we tell each other the most absurd stories with the most serious faces. My wife is very good at it—much better, in fact, than I am. She never gets confused over her dates, and I always do. But when she does find me out, she makes no row at all. I sometimes wish she would; but she merely laughs at me.”
“I hate the way you talk about your married life, Harry,” said Basil Hallward, strolling towards the door that led into the garden. “I believe that you are really a very good husband, but that you are thoroughly ashamed of your own virtues. You are an extraordinary fellow. You never say a moral thing, and you never do a wrong thing. Your cynicism is simply a pose.”
“Being natural is simply a pose, and the most irritating pose I know,” cried Lord Henry, laughing; and the two young men went out into the garden together and ensconced themselves on a long bamboo seat that stood in the shade of a tall laurel bush. The sunlight slipped over the polished leaves. In the grass, white daisies were tremulous.
After a pause, Lord Henry pulled out his watch. “I am afraid I must be going, Basil,” he murmured, “and before I go, I insist on your answering a question I put to you some time ago.”
“What is that?” said the painter, keeping his eyes fixed on the ground.
“You know quite well.”
“I do not, Harry.”